Photo: AP

(Bloomberg) — Novartis AG’s plan to link the payment for a new heart-failure treatment to the medicine’s performance is meeting skepticism from the largest manager of drug insurance benefits in the U.S.

Novartis said Wednesday that it plans to offer an outcomes- based plan for its newly approved drug Entresto. Insurers would initially pay a lower price, followed by an additional payment if Entresto succeeds in keeping patients out of the hospital and reducing associated costs. The drug could cost as much as $4,500 a year and would be taken daily for a patient’s lifetime.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?

Dig Deeper


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.